Table 2.

Crude and adjusted odds ratios for the association between variables and the risk of Pneumocystis Pneumonia

	Univariable analysis		Multivariable analysis
			Forced entering		Stepwise selection
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Disease duration, incremental year	0.94 (0.88–1.01)	0.10	1.10 (0.92–1.32)	0.31
CCI without moderate to severe renal disease	1.65 (1.23–2.22)	< 0.01	1.51 (0.91–2.49)	0.12
Moderate to severe renal disease	4.97 (2.62–9.42)	< 0.01	7.61 (1.80–32.16)	< 0.01	6.73 (1.98–22.92)	< 0.01
Trimethoprim-sulfamethaxazole	< 0.001 (< 0.001–> 999)	0.99	< 0.001 (< 0.001–> 999)	0.99
Glucocorticoidsa
≤ 5 mg/day	Ref.		Ref.		Ref.
5–10 mg/day	8.76 (1.75–43.81)	< 0.01	23.73 (2.18–258.63)	< 0.01	25.88 (2.97–225.33)	< 0.01
> 10 mg/day	90.63 (20.54–399.95)	< 0.01	997.90 (51.32–> 999)	< 0.01	286.58 (28.58–> 999)	< 0.01
Hydroxychloroquine cumulative dose
None	Ref.		Ref.		Ref.
≤ 14 gb	0.56 (0.28–1.14)	0.11	0.56 (0.14–2.26)	0.41	0.69 (0.21–2.24)	0.54
> 14 gb	0.45 (0.21–0.97)	0.04	0.12 (0.02–0.63)	0.01	0.20 (0.05–0.71)	0.01
Sulfasalazine	0.85 (0.10–7.20)	0.88	0.08 (0.00–4.71)	0.22
Cyclophosphamide cumulative dose
None	Ref.		Ref.		Ref.
≤ 1.4 gb	3.18 (1.17–8.62)	0.02	0.42 (0.08–2.15)	0.30	0.64 (0.14–3.01)	0.58
> 1.4 gb	21.87 (6.00–79.81)	< 0.01	12.01 (1.42–101.58)	0.02	11.52 (1.97–67.39)	< 0.01
Methotrexate / Leflunomide	0.79 (0.17–3.62)	0.76	0.29 (0.01–7.94)	0.47
Mycophenolate mofetil/mycophenolic acid	34.11 (7.65–152.19)	< 0.01	38.07 (0.88–> 999)	0.06	50.79 (5.32–484.77)	< 0.01
Cyclosporine	5.03 (2.12–11.92)	< 0.01	3.83 (0.64–23.05)	0.14
Azathioprine	1.02 (0.53–1.96)	0.96	0.57 (0.15–2.26)	0.43
AIC			85		82

Adjusted for age and gender. ^aPrednisolone equivalent. ^bMedian cumulative dose. AIC, Akaike information criterion